REMEGEN

RemeGen closed sharply lower in the afternoon session, falling 5.0% to HKD 82.90, primarily dragged by weakness in the broader biotech sector. The stock initially surged to a morning high of HKD 87.00 but reversed course as selling pressure intensified, ending near the intraday low of HKD 82.90 in a classic 'rally-and-reverse' pattern. The company's Q1 2026 earnings showed net profit surging 236.6% YoY to HKD 372 million, with revenue up 32.1%, reflecting strong fundamental improvement, though operating profit remained negative with a net margin around 50%. At the current price, the stock sits 34.5% below its 52-week high of HKD 126.6, yet has gained 12.6% YTD and holds above both the MA20 (HKD 82.35) and MA60 (HKD 82.29). While recent buyback plans had buoyed sentiment, sector-wide headwinds ultimately capped the upside.

RemeGen staged a single-session rally in the morning session on the Hong Kong Stock Exchange, reaching HKD89.5 as of 10:03 BJ, up 5.05% with a turnover of approximately HKD129 million. The move was catalyzed by a recently announced share buyback plan, building on prior positive sentiment from the preliminary approval of innovative drug inclusion in the medical insurance catalog and a new indication approval. Despite opening at HKD87.0 and briefly dipping to an intraday low of HKD86.3, the stock quickly recovered to the session high of HKD89.5, resulting in an intraday range of 3.7%. At current levels, the stock remains 29.3% below its 52-week high of HKD126.6, yet has rebounded 55.25% from the 52-week low of HKD57.65, and is trading above both the 20-day moving average (HKD80.97) and 60-day moving average (HKD83.0). However, valuation remains elevated with a PE of 34.5x and a PB of 11.4x.

RemeGen surged 10.05% to close at HKD 83.90 on high volume of 5.47 million shares and turnover of HKD 447.8 million, with an intraday range of HKD 78.45 to HKD 83.90. The rally was primarily driven by the announcement of a share buyback plan. The stock opened at HKD 78.25, staged a low-to-high recovery in the morning session, and extended gains in the afternoon to hit the day's high at the close. Financially, Q1 2026 net profit jumped 236.63% YoY to HKD 371.9 million, with revenue up 32.07% to HKD 744.0 million and net profit margin at 49.98%, though operating income remained negative. The stock remains 33.73% below its 52-week high of HKD 126.60, but has reclaimed its 20-day MA (HKD 78.90) and is near the 60-day MA (HKD 83.72), with a YTD gain of 13.92%. However, the stock had fallen 10% and 8% on previous sessions amid sector weakness.

RemeGen (9995.HK) opened sharply lower and continued to weaken, closing down 10.29% at HKD 76.25, leading the decline in Hong Kong's biotech sector. The morning session opened at HKD 84.50 and plunged rapidly, hitting a low of HKD 75.85, with the afternoon session further dipping to HKD 75.30, forming a pattern of initial surge followed by sharp reversal. The stock had rallied over 30% in the past month on positive catalysts including Telitacicept's NMPA approval for Sjögren's disease and preliminary approval for the medical insurance catalog, but today's broad sector weakness triggered profit-taking. Latest earnings showed Q1 2026 operating revenue of HKD 744 million, up 32% YoY, and net profit of HKD 372 million, up 237% YoY, though operating income remained negative. The stock currently trades 39.77% below its 52-week high of HKD 126.60, below both the 20-day MA (HKD 78.15) and 60-day MA (HKD 84.26), with a YTD gain of just 3.53%. Valuation metrics show PB of 9.67x and PE of 29.42x, though the contrast between improving fundamentals and weak price action persists.

RemeGen surged in the morning session, reaching HKD 86.65 by 9:53 BJ, up 5.03% from the previous close of HKD 82.50, with an intraday high of HKD 86.65 and low of HKD 83.10, forming a low-opening, steady-ascending pattern. The rally was driven by recent policy catalysts: preliminary approval for the new medical insurance directory and a new indication approval for Telitacicept. Q1 2026 earnings showed operating revenue of HKD 744M (+32% YoY) and net profit of HKD 372M (+237% YoY), with a net profit margin of 50%. The stock, still 31.5% below its 52-week high of HKD 126.6, has gained 17.7% YTD and now trades above both its 20-day (HKD 76.9) and 60-day (HKD 85.6) moving averages. However, at a trailing P/E of 33.5x and P/B of 11.0x, valuation appears elevated, while operating income remains negative at HKD 25M, signaling that profitability improvement warrants further scrutiny.